Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement

Area of Science:

• Public Health
• Preventive Medicine
• Clinical Recommendations

Background:

• Major Depressive Disorder (MDD) is a significant health concern in children and adolescents.
• Previous recommendations on MDD screening in this age group require updating based on new evidence.

Purpose of the Study:

• To update the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for MDD in children and adolescents.
• To evaluate the benefits and harms of screening and treatment for MDD in pediatric populations.

Main Methods:

• Systematic review of evidence on screening accuracy, benefits, and harms of screening and treatment.
• Focused on primary care-feasible screening tests and treatment modalities including psychotherapy, medications, and collaborative care.
• Included patients aged 7 to 18 years without a prior MDD diagnosis.

Main Results:

• Recommends screening for MDD in adolescents aged 12 to 18 years (B recommendation).
• Screening implementation requires systems for accurate diagnosis, effective treatment, and follow-up.
• Evidence is insufficient to assess screening benefits and harms in children aged 11 years and younger (I statement).

Conclusions:

• Routine screening for MDD is recommended for adolescents aged 12-18.
• Effective systems are crucial for successful screening and treatment implementation.
• Further research is needed to determine the role of screening in younger children.